인간 유도 만능 줄기 세포에서 뇌 미세 혈관 내피 세포의 파생, 확장, 냉동 보존 및 특성화

Executive Industry Relevance

Human iPSC-derived brain microvascular endothelial cells (BMECs) enable the development of ex vivo blood-brain barrier (BBB) models for early-stage CNS drug discovery and mechanistic de-risking. This protocol supports the generation, expansion, and cryopreservation of BMECs, facilitating disease-relevant system modeling and functional validation of BBB properties. The approach enhances predictive confidence for BBB permeability and transporter function, directly impacting portfolio triage and translational research.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of BBB integrity and transporter activity in disease-relevant human systems.
• Supports mechanistic de-risking by modeling patient-specific BBB dysfunction.
• Facilitates functional target validation for CNS drug delivery strategies.
• Provides a platform for hypothesis testing of BBB-related therapeutic mechanisms.

Screening & Assay Development

• Delivers standardized BMEC monolayers for quantitative TEER and efflux transporter assays.
• Enables reproducible assessment of compound permeability across the BBB.
• Supports assay scalability and platform reuse for high-content screening.
• Prepares validated biological systems for downstream co-culture and organoid workflows.

Translational & Preclinical Research

• Aligns in vitro BBB models with translational biomarker endpoints such as TEER and transporter activity.
• Provides continuity from discovery through preclinical validation of CNS drug candidates.
• Enables risk-adjusted advancement decisions based on human-relevant BBB function.
• Supports modeling of BBB dysfunction in neuropsychiatric and neurodegenerative disorders.

Pipeline & Workflow Integration

This protocol positions iPSC-derived BMECs as a bridge from early discovery to preclinical CNS drug evaluation, supporting both target validation and lead identification.

• Discovery Biology: Enables hypothesis testing of BBB mechanisms and pathway clarification in human-derived systems.
• Screening: Provides reproducible, quantitative TEER and transporter activity readouts for compound evaluation.
• Analytics: Delivers standardized measurements for cross-condition comparison and statistical analysis.
• Translational Research: Facilitates alignment with preclinical BBB biomarkers and disease modeling.
• Enterprise Reuse: Establishes a reusable platform for diverse CNS drug discovery and disease modeling initiatives.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in BBB permeability and transporter function for CNS portfolios.
• Operational Value: Standardizes BMEC derivation, expansion, and cryopreservation for reproducible workflows.
• Strategic Value: Improves go/no-go decisions by providing human-relevant BBB data early in the pipeline.
• Portfolio Impact: Enables risk-adjusted prioritization of CNS assets based on functional BBB validation.

Implementation Considerations

• Requires expertise in iPSC culture, differentiation, and endothelial cell biology.
• Needs access to TEER instrumentation, multi-plate readers, and immunocytochemistry infrastructure.
• Demands cross-team standardization of cell density, media, and matrix coatings for reproducibility.
• Adaptation across disease models may require protocol optimization for specific iPSC lines.
• Lower TEER and marker localization after cryopreservation may limit some downstream applications.

Biopharma FAQs